

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.

Express Mail Label: EV 765 980 005 US

Typed or print name

Rachel Mena

Signature



Date

March 14, 2006



PATENT

Attorney Docket No.: 39754-0672A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Andrew Saxon, et al.)	Customer No. 25213
Application No.: 09/847,208)	Art Unit: 1644
Filed: May 1, 2001)	Examiner: Phuong N. Huynh
Title: Fusion Molecules and Treatment of IgE-Mediated Allergic Diseases)	

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97

Mail Stop: RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --

(2) It is being filed within 3 months of entry of a national stage
-- OR --

(3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

a certification as specified in §1.97(e) is provided below; or

a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39754-0672A).

Respectfully submitted,

HELLER EHRLMAN LLP

By: Leslie Mook
Leslie Mook
Reg. No.: 37,047

Dated: March 14, 2006

HELLER EHRLMAN LLP (Customer No.: 25213)
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: 1.650.324.7000
Facsimile: 1.650.324.0638


INFORMATION DISCLOSURE STATEMENT  PTO-1449			ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208			
			APPLICANT: Andrew Saxon, et al.				
			FILING DATE: 05/01/2001		GROUP: 1644		
			U.S. PATENT DOCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Boyce and Austen, "No Audible Wheezing: Nuggets and Conundrums from Mouse Asthma Models," <i>JEM</i> , 201:(12) 1869-1873 (2005).						
	Coffman and Hessel, "Nonhuman Primate Models of Asthma," <i>JEM</i> , 201:(12) 1875-1879 (2005).						
EXAMINER		DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.

Express Mail Label: EV 765 988 707 US

Typed or print name	Jason A. Gonzalez		
Signature		Date	December 13, 2005



PATENT

Attorney Docket No.: 39754-0672A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Andrew Saxon, et al.

) Art Unit: 1644

Application No.: 09/847,208

) Examiner: Phuong N. Huynh

Filed: May 1, 2001

Title: Fusion Molecules and Treatment of IgE-Mediated
Allergic Diseases

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §1.97

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --

(2) It is being filed within 3 months of entry of a national stage
-- OR --

(3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

a certification as specified in §1.97(e) is provided below; or

a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39754-0672A).

Respectfully submitted,

HELLER EHRLMAN LLP

Dated: December 13, 2005

By: Leslie Mook
Leslie Mook
Reg. No.: 37,047

HELLER EHRLMAN LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: 1.650.324.7000
Facsimile: 1.650.324.0638
Customer No.: 25213

INFORMATION DISCLOSURE STATEMENT PTO-1449 	ATTY. DOCKET NO. 39754-0672A		SERIAL NO. 09/847,208	
	APPLICANT: Andrew Saxon, et al.			
	FILING DATE: 05/01/2001		GROUP: 1644	
	U.S. PATENT DOCUMENTS			

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	5,141,648	08/25/1992	Hylarides, et al.	210	635	
	5,358,710	10/25/1994	Sehon, et al.	424	178.1	
	5,512,283	04/30/1996	Byers, et al.	424	171.1	
	5,558,869	09/24/1996	Burks, Jr., et al.	424	276.1	
	5,560,915	10/01/1996	Patterson, et al.	424	275.1	
	5,637,454	06/10/1997	John B. Harley	435	005	
	5,645,820	07/08/1997	David Allen Halfer, et al.	424	041	
	5,672,683	09/30/1997	Friden, et al.	530	350	
	5,736,507	05/07/1998	Anna Maria Boots, et al.	514	002	
	5,843,449	12/01/1998	Anna Maria Boots, et al.	424	185.1	
	5,869,093	02/09/1999	Howard L. Weiner, et al.	424	451	
	5,880,103	03/09/1999	Urban, et al.	514	44	
	5,977,307	11/05/1999	Friden, et al.	530	350	
	6,103,697	08/15/2000	Bergstrand, et al.	514	14	
	6,214,974	04/10/2001	Rosenblum, et al.	530	391.9	
	6,228,373	05/08/2001	Bergstrand, et al.	424	278.1	
	6,228,374	05/08/2001	Bergstrand, et al.	424	278.1	
	6,287,792	09/11/2001	Pardridge, et al.	435	7.5	
	6,372,250	04/16/2002	Pardridge, et al.	424	450	

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 2000/005254	3 February 2000	WIPO	C07K	14/47	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	WO 1999/067293	29 December 1999	WIPO		16/46	<input type="checkbox"/>	<input checked="" type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Alvarez-Fernandez, Marcia, et al., "Inhibition of Mammalian Legumain by Some Cystatins Is Due to a Novel Second Reactive Site", The Journal of Biological Chemistry, Vol. 274, No. 27, Issue of July 2, pp. 19195-19203, 1999
--	---

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
		APPLICANT: Andrew Saxon, et al.	
		FILING DATE: 05/01/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
American Autoimmune Related Diseases Association, Questions and Answers, pp. 1-4, 07/26/2001 (http://www.aarda.org/questions_and_answers.html)			
Resources for Health Professionals: Anaphylaxis, pp. 1-10, 09/18/2001 (http://www.worldallergy.org/professional/allergy_update/anap.../anaphylaxissynopsis.shtml)			
ANSARI, AA, et al., "Epitope Mapping of the Branched Chain Alpha-Ketoacid Dehydrogenase Dihydrolipoyl Transacetylase (BCKD-E2) Protein that Reacts with Sera from Patients with Idiopathic Dilated Cardiomyopathy", (abstract), J Immunol, 153(10):4754-65, 15 November 1994			
AroTec Diagnostics Limited - β 2-Glycoprotein 1 (human), pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5002.htm)			
AroTec Diagnostics Limited - Myeloperoxidase (pANCA) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5009.htm)			
AroTec Diagnostics Limited - Proteinase 3 (cANCA) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5008.htm)			
AroTec Diagnostics Limited - La (SSB) Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5010.htm)			
AroTec Diagnostics Limited - Ro (SSA) Antigen, pp. 1-3, July 11, 2001 (http://webnz.com/arotec/masa5011.htm)			
AroTec Diagnostics Limited - Sm Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5007.htm)			
AroTec Diagnostics Limited - RNP/Sm Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5006.htm)			
AroTec Diagnostics Limited - Scl-70 Antigen, pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5001.htm)			
AroTec Diagnostics Limited - Parietal Cell Antigen (H/K-ATPase), pp. 1-3, July 12, 2001 (http://webnz.com/arotec/masa5004.htm)			
AroTec Diagnostics Limited - Jo-1 Antigen, pp. 1-2, 07/11/2001 (http://webnz.com/arotec/masa5005.htm)			
"Autoantigen Sequences", pp. 1-3, 07/11/2001 (http://129.206.51.31/mb/ana_base.html)			
"Autoimmune Disease: Rapid Progress in our Understanding of Immune Function Promises More Effective Treatments for Autoimmune Disorders", Nature Biotechnology, Vol. 18, pp. IT7-IT9, Supplement 2000			
BARKER RN, et al., "Red Blood Cell Glycophorins as B and T-cell Antigens in Canine Autoimmune Haemolytic Anaemia", (abstract) Vet Immunol Immunopathol, 47(3-4):225-38, August 1995			
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO.	SERIAL NO.
		39754-0672A	09/847,208
		APPLICANT: Andrew Saxon, et al.	
		FILING DATE: 05/01/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
<p>“alphaβ-Crystallin In Multiple Sclerosis”, J. Immunol, Vol. 129-135, pp. 1-5, July 20, 2001 (http://www.albany.net/~tjc/crystalline.html)</p>			
<p>BAJRAMOVIC, JJ, et al., “Presentation of αB-Crystallin to T Cells in Active Multiple Sclerosis Lesions: An Early Event Following Inflammatory Demyelination”, The American Association of Immunologists, Vol 164, pp. 4359-4366, 2000</p>			
<p>BIGAZZI, PE, MD, Lecture on “Autoimmune Disease”, The University of Connecticut, pp. 1-6, July 30, 2001, (http://155.37.1.60/Lectures/PB/Autoimmune.html)</p>			
<p>BONFA, E., et al., “Frequency and Epitope Recognition of Anti-Ribosome P Antibodies from Humans with Systemic Lupus Erythematosus and MRL/lpr Mice are Similar”, (abstract), J Immunol; 140(1):3434-3437, 15 May 1998</p>			
<p>BRIDGES, SL, Jr., et al., “T-Cell Receptor Peptide Vaccination in the Treatment of Rheumatoid Arthritis”, Emerging Therapies for Rheumatoid Arthritis, Vol. 24, pp. 641-650, 1998</p>			
<p>CAMBIER, JC, “Commentary: Inhibitory receptors abound?”, Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 5993-5995, 1997</p>			
<p>CHAPMAN, MARTIN D., et al., “Recombinant Allergens for Diagnosis and Therapy of Allergic Disease”, J Allergy Clin Immunol, pp. 409-418, 2000</p>			
<p>CRITCHFIELD, JM, et al., “T Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis”, Science Feb 25; 263(5150):1139-43, 1994 (abstract)</p>			
<p>DE PALMA, R, et al., “Use Of Altered Peptide Ligands To Modulate Immune Responses As A Possible Immunotherapy For Allergies”, Allergy: 55: Suppl 61: 56-59, 2000</p>			
<p>DECKER, PATRICE, et al., “Inhibition Of Caspase-3-Mediated Poly (ADP-Ribose) Polymerase (PARP) Apoptotic Cleavage By Human PARP Autoantibodies And Effect On Cells Undergoing Apoptosis”, The Journal Of Biological Chemistry, © 2000 by The American Society For Biochemistry And Molecular Biology, Inc., Vol. 275, No. 12, pp. 9043-9046, 24 March 2000</p>			
<p>DIETERICH, W., et al., Identification Of Tissue Transglutaminase As The Autoantigen Of Celiac Disease”, Nat Med; 3(7):797-801, July 1997 (abstract)</p>			
<p>Merck Corp., “Disorders With Type III Hypersensitivity Reactions”, The Merck Manual, Sec. 12, Ch. 148, Hypersensitivity Disorders, July 12, 2001</p>			
<p>DITZEL, HENRIK J., “Human Antibodies In Cancer And Autoimmune Disease”, Immunologic Research; 21(2-3):185-193, 2000</p>			
<p>EARNshaw WC, et al., “Identification Of A Family Of Human Centromere Proteins Using Autoimmune Seras From Patients With Scleroderma”, (abstract) Chromosoma, 91(3-4):313-321, 1985</p>			
<p>ELKON, KB, et al., “Lupus Autoantibodies Target Ribosomal P Proteins”, (abstract) J Exp Med, 162(2): 459-471, August 1 1985</p>			
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
		APPLICANT: Andrew Saxon, et al.	
		FILING DATE: 05/01/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
FABIEN N., et al., "Autoantibodies Directed Against The Ribosomal P Proteins Are Not Only Directed Against A Common Epitope Of The P0, P1 And P2 Proteins", (abstract) <i>J Autoimmune</i> , 13(1): 103-110, August 1999			
FARIA AM, et al., "Oral Tolerance: Mechanisms And Therapeutic Applications", (abstract), <i>Adv Immunol</i> , 73:153-264, 1999			
FRAMPTON, G., et al., "Identification Of Candidate Endothelial Cell Autoantigens In Systemic Lupus Erythematosus Using A Molecular Cloning Strategy: A Role For Ribosomal P Protein P0 As An Endothelial Cell Autoantigen", <i>Rheumatology (Oxford)</i> , (abstract) 39(10):1114-1120, October 2000			
GIOVANNONI, G., et al., "Multiple Sclerosis And Its Treatment", (abstract) <i>J R Coll Physicians Lond</i> , 33(4):315-22, Jul-Aug 1999			
GOLD, DANIEL P., et al., "T-Cell Receptor Peptides As Immunotherapy For Autoimmune Disease", <i>Critical Reviews™ In Immunology</i> , (abstract) 17:507-510, 1997			
GOLD, DP, "Results Of A Phase I Clinical Trial Of A T-Cell Receptor Vaccine In Patients With Multiple Sclerosis. II. Comparative Analysis Of TCR Utilization In CSF T-Cell Populations Before And After Vaccination With A TCRV Beta 6 CDR2 Peptide", (abstract) <i>J Neuroimmunol</i> , 76(1-2):29-38, July 1997			
GOLD, HA, et al., "The RNA Processing Enzyme RNase MRP Is Identical to the Th RNP And Related to RNase P", (abstract) <i>Science</i> , 245(4924):1377-80, 22 September 1989			
GOTTLIEB, A.B., et al., "Anti-CD4 Monoclonal Antibody Treatment of Moderate to Severe Psoriasis Vulgaris: Results of a Pilot, Multicenter, Multiple-Dose, Placebo-Controlled Study", (abstract) <i>J Am Acad Dermatol</i> , 43(4):595-604, October 2000			
GUNNARSSON, ANDREAS, et al., "Molecular Properties Of The Goodpasture Epitope", <i>The Journal Of Biological Chemistry</i> , Vol. 275, No. 40, pp. 30844-30848, 6 October 2000			
HASELDEN, B.M., et al., "Peptide-Mediated Immune Responses in Specific Immunotherapy", <i>Int Arch Allergy Immunol</i> , 122(4):229-37, 2000			
HELLMARK, T., et al., "Characterization of Anti-GBM Antibodies Involved in Goodpasture's Syndrome", (abstract) <i>Kidney Int</i> , 46(3):823-9, September 1994			
HIRANO, T., et al., "Human Tissue Distribution of TA02, which is Homologous with a New Type of Aspartic Proteinase, Napsin A", (abstract) <i>Jpn J Cancer Res</i> , 91(10):1015-21, October 2000			
"Histones and Subclasses", July 30, 2001, Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0019.htm)			
HUGHES, G.R., "The Antiphospholipid Syndrome: Ten Years On", (abstract) <i>Lancet</i> , 342(8867):341-344, August 7, 1993			
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	KARLSSON, F.A., et al., "Major Parietal Cell Antigen in Autoimmune Gastritis with Pernicious Anemia is the acid-producing H ⁺ , K ⁺ adenosine Triphosphatase of the Stomach", (Abstract) J Clin Invest, 81(2):475-9, February 1988
	KOZLOWSKI, MAYA, et al., "SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain", Molecular and Cellular Biology, pp. 2089-2099, Vol. 18, No. 4, April 1998
	Kronus, "Addison's Disease", Enzyme Steroid 21-Hydroxylase (21-OH) Antibody, (http://www.kronus.com/products/addisons.html), July 30, 2001
	Kronus, "Celiac Disease", Tissue Transglutaminase (tTg) Autoantibody, (http://www.kronus.com/products/celiac.html), July 30, 2001
	Kronus, "Diabetes", (http://www.kronus.com/products/diabetes.html), July 30, 2001
	Kronus, "Neuromuscular", Myasthenia Gravis, (http://www.kronus.com/products/neuromuscular.html), July 30, 2001
	Kronus, "Thyroid Autoimmune", (http://www.kronus.com/products/thyroid-auto.html), July 30, 2001
	KROGSGAARD, M., et al., "Visualization of Myelin Basic Protein (MBP) T Cell Epitopes in Multiple Sclerosis Lesions Using a Monoclonal Antibody Specific for the Human Histocompatibility Leukocyte Antigen (HLA)-DR2-MBP 85-99 complex", (abstract), J Exp Med, April 17;191(8):1395-412, 2000
	LARCHE, MARK, "Specific Immunotherapy", British Medical Bulletin, 56 (No. 4): 1019-1036, 2000
	MALBEC, ODILE, et al., "The SH2 Domain-containing Inositol 5-Phosphatase SHIP1 Mediates Cell Cycle Arrest by Fc γ RIIB", JBC Papers in Press., pp. 1-29, May 18, 2001
	MCNEIL, H. PATRICK, et al., "Anti-Phospholipid Antibodies are Directed Against a Complex Antigen that Includes a Lipid-Binding Inhibitor of Coagulation: β_2 -Glycoprotein I (apolipoprotein H)", Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 4120-4124, Medical Sciences, June 1990
	MIMORI, T., et al., "Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from Patients with Rheumatic Disorders", (abstract) J. Biol. Chem., 261(5):2274-8, February 15, 1986
	MISAKI, Y., et al., "The 56K Autoantigen is Identical to Human Annexin XI", (Abstract) J. Biol. Chem., 269(6):4240-6, 11 February 1994
	Immunovision (Brochure), "Mitochondrial Antigen", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0020.htm), July 30, 2001

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
	39754-0672A	09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
MU, F.T., et al., "EEA1, an Early Endosome-Associated Protein. EEA1 is a Conserved Alpha-Helical Peripheral Membrane Protein Flanked by Cysteine "Fingers" and Contains a Calmodulin-Binding IQ Motif", <i>J. Biol. Chem.</i> , 270(22):13503-11, June 2 1995		
Immunovision (Brochure), "nRNP", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0020.htm)		
NAKAJIMA, ATSUO, et al., "Antigen-Specific T Cell-Mediated Gene Therapy in Collagen-Induced Arthritis", <i>The Journal of Clinical Investigation</i> , Vol. 107, No. 10, pp. 1293-1301 May 2001		
NEWKIRK, MARIANNA M., et al., "Autoimmune Response to U1 Small Nuclear Ribonucleoprotein (U1 snRNP) Associated with Cytomegalovirus Infection", <i>Arthritis Res.</i> , 3: 253-258, July 30 2001		
NORMAN, PHILIP S., "Therapeutic Potential of Peptides in Allergic Disease", <i>Annals of Allergy</i> , Vol. 71, pp. 330-333, September 1993		
OKANO, Y., et al., "Autoantibody to Th Ribonucleoprotein (Nucleolar 7-2 RNA Protein Particle) in Patients with Systemic Sclerosis", <i>Arthritis Rheum.</i> , 33(12):1822-8, December 1990, (abstract)		
ONO, S.J., "Molecular Genetics of Allergic Diseases", <i>Annu Rev Immunol.</i> , 18:347-66, 2000, (abstract)		
ROCK, KENNETH L., et al., "Degradation of Cell Proteins and the Generation of MHC Class I-Presented Peptides", <i>Annu. Rev. Immunol.</i> , 17:739-79, 1999, (abstract)		
CASCIO P., et al., "26Sproteasomes and Immunoproteasomes Produce Mainly N-Extended Cessions of an Antigenic Peptide", <i>EMBO J.</i> , 20(10):2357-2366, May 15, 2001, (abstract)		
SERWOLD T., et al., "ER Aminopeptidases Generate a Unique Pool of Peptides for MHC Class I Molecules", <i>Nat. Immunol.</i> , July 2001, (abstract)		
YEWDELL, JW., et al., "Not Such a Dismal Science: The Economics of Protein Sythesis, Folding, Degradation and Antigen Processing", <i>Trends Cell Biol.</i> , 11(7):294-297, July 2001, (abstract)		
FIEBIGER E., et al., "Cytokines Regulate Proteolysis in Major Histocompatibility complex Class II-Dependent Antigen Presentationby Dendritic Cells" <i>J. Exp. Med.</i> , 193(8):881-892, April 16, 2001, (abstract)		
STOLTZE L., et al., "Two New Proteases in the MHC Class I Processing Pathway", <i>Nat. Immunol.</i> , 1(5):413-418, November 2000, (abstract)		
MUNO D., et al., "Generation of both MHC Class I- and Class II-Restricted Antigenic Peptides from Exogenously Added Ovalbumin in Murin Phagosomes", <i>FEBS Lett.</i> , 478(1-2):178-182, July 28, 2000, (abstract)		
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	MANOURY B., et al., "An Asparaginyl Endopeptidase Processes a Microbial Antigen for Class II MHC Presentation", Nature, 396(6712):625-627, December 17, 1998, (abstract)	
	Auto Immune, Inc., "Overview of Oral tolerance Therapy" Research and Development – OT Technology, July 30, 2001, (http://www.autoimmuneinc.com/R_D/tech.html)	
	Immunovision (Brochure), " PCNA Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, (http://www.immunovision.com/pg0061.htm)	
	PISETSKY, D.S., "The Role of Bacterial DNA in Autoantibody Induction", (abstract) Curr Top Microbiol Immunol, 247:143-155, 2000	
	RICKERT, M., et al., "Fusion Proteins for Combined Analysis of Autoantibodies to the 65-kda Isoform of Glutamic Acid Decarboxylase and Islet Antigen-2 in Insulin-Dependent Diabetes Mellitus", Clin Chem, 47(5):926-34, May 2001, (abstract)	
	Immunovision (Brochure), "Ribosomal P Antigen", Purified Antigens for Autoimmune Testing, July 30, 2001, (http://www.immunovision.com/pg0021.htm)	
	RIDER, LISA G., et al., "Laboratory Evaluation of the Inflammatory Myopathies", Clinical and Diagnostic Laboratory Immunology, Vol. 2, No. 1, p. 1-9, Jan. 1995	
	RIESE, RICHARD J., et al., "Cathepsin S Activity Regulates Antigen Presentation And Immunity", J. Clin. Invest., Vol. 101, No. 11, 2351-2363, June 1998	
	Immunovision (Brochure), "Ro/SS-A Antigen", July 30, 2001, (http://www.immunovision.com/pg0013.htm)	
	NOEL ROSE, et al., The Autoimmune Diseases: Table of Contents, Third Edition, Academic Press 1998	
	SARIC, TOMO, et al., "MHC Class I-Presented Antigenic Peptides are Degraded in Cytosolic Extracts Primarily by Thimet Oligopeptidase", JBC Papers in Press., Published July 30, 2001	
	Immunovision (Brochure), "Scl-70 Antigen", Purified Antigens for Autoimmune Testing" (http://www.immunovision.com/pg0017.htm), July 30, 2001	
	Immunovision (Brochure), "SMITH (sm) Antigen", Purified Antigens for Autoimmune Testing" (http://www.immunovision.com/pg0015.htm), July 30, 2001	
	SELA, M., "Specific Vaccines Against Autoimmune Diseases", C R Acad Sci III; 322(11):933-8, November 1999, (abstract)	
	SCHUPPAN, D, et al., "Identification of the Autoantigen of Celiac Disease", Ann N Y Acad Sci., 859:121-6, 17 November 1998, (abstract)	
	STEINMAN, L., "Multiple Sclerosis: a Coordinated Immunological Attack Against Myelin in the Central Nervous System", Cell, 85(3):299-302, May 3 1996, (abstract)	
EXAMINER	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO. 39754-0672A	SERIAL NO. 09/847,208
	APPLICANT: Andrew Saxon, et al.	
	FILING DATE: 05/01/2001	GROUP: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	STEINMAN, L., et al., "Prospects for Specific Immunotherapy in Myasthenia Gravis" FASEB J.; 4(10):2726-31, July 1990, (abstract)
	STENMARK, HARALD, et al., "Endosomal Localization of the Autoantigen EEA1 is Mediated by a Zinc-Binding FYVE Finger", The Journal of Biological Chemistry, Vol. 271, No. 39, pp. 24048-24054, September 27 1996
	Tan EM, "Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology", (abstract), Adv Immunol 1989, 44:93-151
	TARGOFF IN, "Autoantibodies to Aminoacyl-Transfer RNA Synthetases for Isoleucine and Glycine. Two Additional Synthetases are Antigenic in Myositis; J Immunol, 144(5):1737-1743, 1 March 1990, (abstract)
	National Institute of Allergy and Infectious Diseases, "Understanding Autoimmune Disease - What are some Examples of Autoimmune Diseases: Rheumatoid Arthritis. (http://www.niaid.nih.gov/publications/autoimmune/examples.htm), July 11, 2001
	VAN SECHEL, ARIANNE C., et al., "EBV-Induced Expression and HLA-DR-Restricted Presentation by Human B Cells of aB-Crystallin, a Candidate Autoantigen in Multiple Sclerosis", The American Association of Immunologists, 1999
	VAN VENROOIJ, W.J., et al., "Manual of Biological Markers of Disease", Table of Contents, Kluwer Academic Publishers,
	VAN VENROOIJ, W.J., Venroij Research Team, Research Topics, General Introduction, "Autoantigens", (abstract), Department of Biochemistry, University of Nijmegen, 11 July 2001
	WALLNER, BARBARA P., Short Analytical Review, "Peptide Therapy for Treatment of Allergic Diseases, Clinical Immunology and Immunopathology, Vol. 80, No. 2, August, pp. 105-109, 1996
	WARDROP, III, R.M., et al, "Oral Tolerance in the Treatment of Inflammatory Autoimmune Disease, Inflamm. res., 48, pp. 106-119, 1990
	YAMAMOTO, A.M., et al., " Anti-Titin Antibodies in Myasthenia Gravis: Tight Association with Thymoma of Nonthymoma Patients", Archives of Neurology, Vol 58, No.6, June 2001
	GERMAIN, R.N., "The T Cell Receptor for Antigen: Signaling and Ligand Discrimination", The Journal of Biological Chemistry, Vol. 276, No. 38, pp. 35223-35226, July 2, 2001
	Immunovision (Brochure), "La/SS-B", Purified Antigens for Autoimmune Testing, (http://www.immunovision.com/pg0014.htm), July 30, 2001
	ROSE, N.R., "The Autoimmune Diseases: A Discussion of the Causes and Treatment of Autoimmune Diseases", American Autoimmune Related Diseases Associate, July 26, 2001
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

EXPRESS MAIL NO.: EL 993 630 448 US -- DATE MAILED: December 9, 2005

Attorney's Docket No.: 39754-0672A

Applicant(s): Andrew Saxon, et al.

Title: Fusion Molecules and Treatment of IgE-Mediated Allergic Diseases

Application No.: 09/847,208


Filing Date: May 1, 2001

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please place the U.S. Receiving Office date stamp hereon to acknowledge receipt of the following:

1. Transmittal Form
2. Fee Transmittal
3. Information Disclosure Statement with PTO-1449
4. 12 References as Cited
5. Return Receipt Postcard



RECEIVED


DEC 10 2005

H.E.W.M. LLP

COPY**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA on the date indicated below.

Express Mail Label: EL 993 630 448 US

Typed or print name	Jason A. Gonzalez		
Signature		Date	December 9, 2005

PATENT**Attorney Docket No.: 39754-0672A****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****PATENT APPLICATION**

Inventor(s): Andrew Saxon, et al.)
Application No.: 09/847,208) Art Unit: 1644
Filed: May 1, 2001) Examiner: Phuong N. Huynh
Title: Fusion Molecules and Treatment of IgE-Mediated)
Allergic Diseases)

INFORMATION DISCLOSURE STATEMENT**UNDER 37 C.F.R. §1.97**

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

(1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --

(2) It is being filed within 3 months of entry of a national stage
-- OR --

(3) It is being filed before the mail date of the first Office Action on the merits
-- OR --

(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

a certification as specified in §1.97(e) is provided below; or

a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No.: 39754-0672A).

Respectfully submitted,

HELLER EHRMAN LLP

Dated: Dec 9, 2005

By: Leslie Mooi
Leslie Mooi
Reg. No.: 37,047

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
Telephone: 1.650.324.7000
Facsimile: 1.650.324.0638
Customer No.: 25213

INFORMATION DISCLOSURE STATEMENT PTO-1449	ATTY. DOCKET NO.	SERIAL NO.
	39754-0672A	09/847,208
	APPLICANT: Andrew Saxon, et al.	
FILING DATE: 05/01/2001	GROUP: 1644	

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	2005/0250934	11/10/2005	Chang Yi Wang, et al.	530	387.1	

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	ASHMAN, ROBERT F., et al., "Fc Receptor Off Signal in the B Cell Involves Apoptosis", The Journal of Immunology, Vol.157, pp. 5-11, 1996
	BOWIE, JAMES U., et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", Science, Vol. 247, pp.1306-1310, 16 March 1990
	CUNNINGHAM, BRIAN C., et al., "High-Resolution Epitope Mappin of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis", Science, Vol. 244, pp. 1081-1085, 2 June 1989
	ELLISON, J., et al., "Nucleotide Sequence of a Human Immunoglobulin C ₄ Gene", DNA, Vol. 1, No. 1, 1981
	JI, TAE H., et al., "Bifunctional Reagents", Methods of Enzymology, Vol. 91, pp. 581-609, 1983
	McKNIGHT, STEVEN LANIER, "Molecular Zippers in Gene Regulation", Scientific American, pp. 54-64, April 1991,
	U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, "Sequences of Proteins of Immunological Interest", Vol. II and Vol. III, Fifth Edition, Table of Contents, pp. iii-xi, 1991
	WAN, TOMMY, et al., "The Crystal Structure of IgE Fc Reveals an Asymmetrically Bent Conformation", Nature Immunology, Vol. 3, No. 7, pp. 681-686, July 2002
	WARREN, KG, et al., "Administration of Myelin Basic Protein Synthetic Peptides to Multiple Sclerosis Patients", (abstract), J. Neurol. Sci., Vol. 133, No. 1-2, pp.85-94, November 1995
	SHINGO YABUCHI, et al., "Anti-Cd23 Monoclonal Antibody (IgE Inhibition Involves the Fc Portion of the Molecules", Abstract 597, J. Allergy Clin. Immunol., Volume 107, No. 2, February 2001
	ZHU, DAOCHENG, et al., "A Novel Human Ig Fc γ -Fc ϵ Chimeric Fusion Protein Inhibits Fc ϵ RI-Mediated Degranulation", (abstract), May 4-7, 2001
	ZHU, DAOCHENG, et al., "A Novel Ig Fc γ -Fc ϵ Chimeric Fusion Protein Inhibits Fc ϵ RI Mediated Degranulation", Abstract 273, Clinical Immunology, Vol.99, No.1, pg 193, April 19, 2001

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

COPY

EXPRESS MAIL NO.: EV 765 988 707 US - DATE MAILED: December 13, 2005
Attorney's Docket No.: 39754-0672A

Applicant(s): Andrew Saxon, et al.

Title: Fusion Molecules and Treatment of IgE-Mediated Allergic Diseases



Application No.: 09/847,208
Filing Date: May 1, 2001

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

DEC 19 2005

H.E.W.M. LLP



Sir:

Please place the U.S. Receiving Office date stamp hereon to acknowledge receipt of the following:

1. Transmittal Form
2. Fee Transmittal
3. Information Disclosure Statement with PTO-1449
4. 106 References Enclosed
5. Return Receipt Postcard

BEST AVAILABLE COPY